ExonHit Launches Human Genome-Wide SpliceArray™
The SpliceArray™ can monitor over 23,000 human genes covering over 130,000 expressed transcripts and requires over 6 million probes to help elucidate diversity of the human proteome.
ExonHit Therapeutics S.A. has announced the availability of its new SpliceArray™ which will enable the research and clinical communities to proceed with the comprehensive analysis of the human genome.
This SpliceArray™, available through portfolio of the companies’ genomic services, can provide an approach to detect all known and expressed transcripts.
The Human GW SpliceArray™ monitors over 23,000 human genes covering over 130,000 expressed transcripts and requires over 6 million probes to help elucidate the enormous diversity of the human proteome.
According to Company, this new design, manufactured on the Affymetrix platform, now expands its product offering and provides researchers the opportunity to obtain gene expression results at a resolution previously unattainable on a single microarray by interrogating both exons and splice junctions.
"ExonHit continues to expand its catalogue of arrays for its genomics services. This most recent achievement represents a great step forward for all scientists who work on elucidating the information from the human genome sequencing effort but also for ExonHit's own drug and diagnostic discovery programs. This genome wide SpliceArray™ is available through ExonHit's service laboratory and our discovery collaboration programs for therapeutic targets and biomarkers" said Dr. Laurent Bracco, Executive Vice President of Technology at ExonHit Therapeutics.
"Our commitment is to advance human healthcare through the identification of high quality targets and biomarkers involved in disease by understanding the diversity caused by alternative splicing. This new SpliceArray™, a major component of our discovery engine, will allow us to further accelerate our patent estate to diagnose chronic diseases and will reinforce considerably our capabilities in the field of pharmacogenomics" stated Dr. Bruno Tocque, CEO of ExonHit Therapeutics."
